Details of the Drug

General Information of Drug (ID: DMU03WD)

Drug Name

IO-202

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]
Chronic myelomonocytic leukaemia	2A40	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte immunoglobulin-like receptor B4 (LILRB4)	TTREOKA	LIRB4_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04372433) IO-202 as Monotherapy in Patients in AML and CMML. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Immune-Onc Therapeutics.